Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Identifying "super responders" in pulmonary arterial hypertension.

Halliday SJ, Hemnes AR.

Pulm Circ. 2017 Apr-Jun;7(2):300-311. doi: 10.1177/2045893217697708. Epub 2017 May 30.

2.

Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.

Gao XF, Zhang JJ, Jiang XM, Ge Z, Wang ZM, Li B, Mao WX, Chen SL.

Patient Prefer Adherence. 2017 May 8;11:871-885. doi: 10.2147/PPA.S133288. eCollection 2017.

3.

Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Badlam JB, Bull TM.

Ther Adv Chronic Dis. 2017 Feb;8(2-3):47-64. doi: 10.1177/2040622317693218. Epub 2017 Mar 1. Review.

4.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

5.

Swift and Complete Healing of Digital Ulcers after Macitentan Treatment.

Giner Serret E.

Case Rep Rheumatol. 2016;2016:1718309. Epub 2016 Nov 22.

6.

Lung Transplantation for Scleroderma-related Lung Disease.

Richardson CB, Singer JP.

Curr Respir Care Rep. 2014 Sep;3(3):79-87. Epub 2014 Jun 22.

7.

NT-proBNP in Children With Left to Right Shunt and Dilated Cardiomyopathy.

Koura HM, Abdalla NM, Hamed Ibrahim M, Abo Hashish MM, Zaki SM.

Iran J Pediatr. 2016 May 15;26(3):e4485. doi: 10.5812/ijp.4485. eCollection 2016 Jun.

8.

Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.

Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, Blevins A, Schmidt GA, Singh S, Gerke AK.

Chest. 2017 Jan;151(1):90-105. doi: 10.1016/j.chest.2016.08.1461. Epub 2016 Sep 9. Review.

PMID:
27615023
9.

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP.

Ann Rheum Dis. 2017 Feb;76(2):422-426. doi: 10.1136/annrheumdis-2015-209087. Epub 2016 Jul 25.

10.

2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Hsu CH, Ho WJ, Huang WC, Chiu YW, Hsu TS, Kuo PH, Hsu HH, Chang JK, Cheng CC, Lai CL, Liang KW, Lin SL, Sung HH, Tsai WC, Weng KP, Hsieh KS, Yin WH, Lin SJ, Wang KY.

Acta Cardiol Sin. 2014 Sep;30(5):401-44.

11.

Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.

Kim JS, McSweeney J, Lee J, Ivy D.

Pediatr Crit Care Med. 2016 Mar;17(3 Suppl 1):S89-100. doi: 10.1097/PCC.0000000000000622. Review.

12.

Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis.

Zhang H, Li X, Huang J, Li H, Su Z, Wang J.

Medicine (Baltimore). 2016 Jan;95(4):e2575. doi: 10.1097/MD.0000000000002575. Review.

13.

The limits of oral therapy in pulmonary arterial hypertension management.

Liu QQ, Jing ZC.

Ther Clin Risk Manag. 2015 Nov 23;11:1731-41. doi: 10.2147/TCRM.S49026. eCollection 2015. Review.

14.

Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center.

Chin KM, Ruggiero R, Bartolome S, Velez-Martinez M, Darsaklis K, Kingman M, Harden S, Torres F.

Pulm Circ. 2015 Sep;5(3):513-20. doi: 10.1086/682224.

15.

Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study.

Hay BR, Pugh ME, Robbins IM, Hemnes AR.

Chest. 2016 Mar;149(3):660-6. doi: 10.1378/chest.15-1051. Epub 2016 Jan 6.

16.

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102-10. doi: 10.1164/rccm.201507-1398OC.

17.

Pulmonary hypertension: diagnostic and therapeutic challenges.

Bazan IS, Fares WH.

Ther Clin Risk Manag. 2015 Aug 17;11:1221-33. doi: 10.2147/TCRM.S74881. eCollection 2015. Review.

18.

Optimal management of digital ulcers in systemic sclerosis.

Abraham S, Steen V.

Ther Clin Risk Manag. 2015 Jun 15;11:939-47. doi: 10.2147/TCRM.S82561. eCollection 2015. Review.

19.

Epoprostenol sodium for treatment of pulmonary arterial hypertension.

Saito Y, Nakamura K, Akagi S, Sarashina T, Ejiri K, Miura A, Ogawa A, Matsubara H, Ito H.

Vasc Health Risk Manag. 2015 May 14;11:265-70. doi: 10.2147/VHRM.S50368. eCollection 2015. Review.

20.

Prostanoid therapies in the management of pulmonary arterial hypertension.

LeVarge BL.

Ther Clin Risk Manag. 2015 Mar 31;11:535-47. doi: 10.2147/TCRM.S75122. eCollection 2015. Review.

Supplemental Content

Support Center